20201221 Filipino worker dies in drug firm blaze
Taiwan Dec 21 2020 “Building” “Factories”
Dead : dead 1 to 4 Burnout : 1 to 29 Injured : injured 0 or unknown
Filipino worker dies in drug firm blaze
Updated: 2020–12–21
SCI Pharmtech Inc spokesman Deiter Yang speaks at a news conference at the Taiwan Stock Exchange in Taipei yesterday.
Photo: CNA
Shares of drug developer SCI Pharmtech Inc (SCI, 旭富製藥) yesterday plunged by their daily limit to NT$112 after a fire broke out on Sunday at the company’s plant in Taoyuan’s Lujhu District (蘆竹), killing a Filipino worker and causing about NT$800 million (US$28.05 million) in losses.
The fire began at about noon when the production lines were processing chemical solutions, the Taoyuan-based company said.
Because of the chemicals stored in the plant and strong winds, sporadic explosions occurred and the blaze soon spread to the factories of four other companies.
Taoyuan firefighters said they expect to bring the fire under control this afternoon.
SCI Pharmtech spokesman Deiter Yang (楊文禎) told a news conference yesterday that a Filipino worker died early yesterday after being treated for third-degree burns covering 90 percent of his body.
Another employee, a Taiwanese man, was discharged from hospital after being treated for burns to his hand, Yang said.
The company estimated about NT$800 million in losses because of damage to its plant, but added that it should be able to obtain full compensation from insurance companies.
Still, it would take at least six months to rebuild the plant, as most production lines were damaged by the fire, it said.
It estimated another NT$600 million in lost orders in the first quarter, Yang said.
The company has about NT$250 million in finished products, but it needs to assess their quality after the fire, he added.
The Lujhu plant employs about 270 workers, who will all be paid in full up to the Lunar New Year holiday in February, Yang said.
As production has been suspended, the company would evaluate whether it needs to adopt furlough programs, he said.
The fire also damaged the factories of Tao Yuan Paper Manufacturing Co (桃園紙廠), Tung Yang Machine Industry Co (東陽精機), Gwo Chern Industrial Co (國晟工業) and Hong Li International Knitting Co (鴻利國際針織).
SCI Pharmtech is waiting for damage reports from the four before it could determine compensation, Yang said.
The company has NT$30 million in public liability insurance claims for damage to nearby factories, he added.
A subsidiary of local conglomerate Mercuries & Associates Ltd (三商行) and led by chairman Wong Wei-chyun (翁維駿), SCI Pharmtech produces active pharmaceutical ingredients (APIs), cannabidiol intermediates and specialty chemicals.
The company reported cumulative revenue of NT$2.61 billion in the first 11 months of this year, up 18.19 percent from NT$2.21 billion in the same period last year, thanks to steady shipments of APIs for hydroxychloroquine — a medicine used to treat or prevent malaria, lupus and rheumatoid arthritis, as well as mild cases of COVID-19 — and stable sales of other APIs used in drugs for treating epilepsy and depression.
Net profit in the first three quarters of this year was NT$638.92 million, compared with NT$481.6 million in the same period last year, or earnings per share of NT$8.04, compared with NT$6.06 a year earlier, company data showed.
As of yesterday, the company’s shares had risen 2.75 percent this year, underperforming the main bourse, which rose 19.9 percent, Taiwan Stock Exchange data showed.A subsidiary of local conglomerate Mercuries & Associates Ltd (三商行) and led by chairman Wong Wei-chyun (翁維駿), SCI Pharmtech produces active pharmaceutical ingredients (APIs), cannabidiol intermediates and specialty chemicals.
The company reported cumulative revenue of NT$2.61 billion in the first 11 months of this year, up 18.19 percent from NT$2.21 billion in the same period last year, thanks to steady shipments of APIs for hydroxychloroquine — a medicine used to treat or prevent malaria, lupus and rheumatoid arthritis, as well as mild cases of COVID-19 — and stable sales of other APIs used in drugs for treating epilepsy and depression.
Net profit in the first three quarters of this year was NT$638.92 million, compared with NT$481.6 million in the same period last year, or earnings per share of NT$8.04, compared with NT$6.06 a year earlier, company data showed.
As of yesterday, the company’s shares had risen 2.75 percent this year, underperforming the main bourse, which rose 19.9 percent, Taiwan Stock Exchange data showed.
Web Source: Taipei Times
https://www.taipeitimes.com/News/front/archives/2020/12/22/2003749159